泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301263 泰恩康

已收盘 12-16 15:00:00

{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":27.14,"timestamp":1765868601000,"preClose":27.3,"halted":0,"volume":2861500,"delay":0,"changeRate":-0.0059,"floatShares":304000000,"shares":425000000,"eps":0.0548,"marketStatus":"已收盘","change":-0.16,"latestTime":"12-16 15:00:00","open":27.4,"high":27.42,"low":26.86,"amount":77671200,"amplitude":0.0205,"askPrice":27.15,"askSize":121,"bidPrice":27.14,"bidSize":27,"shortable":0,"etf":0,"ttmEps":0.0548,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"adjPreClose":27.3,"symbolType":"stock","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":30.03,"lowLimit":24.57,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":425497500,"isCdr":false,"pbRate":6.7,"roa":"--","peRate":495.255474,"roe":"1.79%","epsLYR":0.26,"committee":-0.006428,"marketValue":11548000000,"turnoverRate":0.0094,"status":1,"floatMarketCap":8239000000},"requestUrl":"/m/hq/s/301263/tweets","defaultTab":"tweets","newsList":[{"id":"2590311352","title":"泰恩康(301263.SZ)：吲哚布芬片境内生产药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590311352?lang=zh_cn&edition=full","pubTime":"2025-12-09 17:17","pubTimestamp":1765271862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局签发的吲哚布芬片境内生产药品注册上市许可申请《受理通知书》，国家药监局对上述药品的药品注册上市许可申请进行了审查，决定予以受理。公告显示，吲哚布芬片是一种血小板聚集抑制剂，通过可逆性抑制环氧化酶及多种诱导剂，降低血栓风险，用于动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成。也可用于血液透析时预防血栓形成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰恩康(301263.SZ)：吲哚布芬片境内生产药品注册上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2589862466","title":"泰恩康：和胃整肠丸国产化生产注册批件预计2026年上半年获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2589862466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589862466?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:00","pubTimestamp":1764921625,"startTime":"0","endTime":"0","summary":"投资者提问：董秘，你好，公司和胃整肠丸批准证明文件11月26日已送达，为什么现在还不公告？泰恩康回复：您好，11月26日获批的是和胃整肠丸的一次性进口批件，并非国产化的生产批件。和胃整肠丸的国产化生产注册批件预计将在2026年上半年获批，和胃整肠丸转为自主生产后，预计毛利率从80%左右提升至90%以上。公司将逐步进行全国性的推广，争取将和胃整肠丸打造为国内急性肠胃用药领域的知名头部品牌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500019089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2588016202","title":"泰恩康：已被纳入中证1000指数拟生效样本范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2588016202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588016202?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:24","pubTimestamp":1764750261,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康(301263)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司被调入中证1000指数了吗？泰恩康回复：您好，公司已被纳入中证1000指数拟生效样本范围，将于2025年12月15日起生效。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300021760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000688.SH","159845","000905.SH","512880","BK0250","512510","159967","399006","515890","399852","399001","510880","000300.SH","000001.SH","510300","301263","000852.SH"],"gpt_icon":0},{"id":"2586720784","title":"泰恩康(301263.SZ)：巴瑞替尼片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586720784","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586720784?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:49","pubTimestamp":1764319757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus激酶(JAK)抑制剂，可阻断一种或多种JAK激酶家族成员的活性，从而抑制激活炎症的途径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2585435102","title":"【机构调研记录】长城基金调研奥比中光、泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585435102?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:02","pubTimestamp":1763942544,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月21日披露的机构调研信息，长城基金近期对2家上市公司进行了调研，相关名单如下：1）奥比中光 调研纪要：3D视觉技术通过融合深度信息与高分辨率成像，可实现对物体尺寸、距离、姿态等空间属性的精准捕捉，小型化、高性能、高度集成化有望成为未来趋势。2）泰恩康 调研纪要：CKB有望获批首个2-12岁儿童白癜风创新药，联合光疗实现“1+1>2”疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400000278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","301263","BK0250","688322"],"gpt_icon":0},{"id":"2585156435","title":"【机构调研记录】宏利基金调研泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2585156435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585156435?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:01","pubTimestamp":1763942499,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月21日披露的机构调研信息，宏利基金近期对1家上市公司进行了调研，相关名单如下：1）泰恩康 调研纪要：CKB有望获批首个2-12岁儿童白癜风创新药，联合光疗实现“1+1>2”疗效。旗下最近一年表现最佳的公募基金产品为宏利成长混合，最新单位净值为3.42，近一年增长80.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400000235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2584867691","title":"泰恩康(301263.SZ)控股子公司CKBA乳膏申报儿童白癜风临床试验获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2584867691","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584867691?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:17","pubTimestamp":1763626629,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司控股子公司江苏博创园生物医药科技有限公司(简称“博创园”)于近日收到国家药品监督管理局签发的受理通知书，同意受理博创园提交的CKBA乳膏联合窄谱中波紫外线(简称“NB-UVB”)在2-12岁(含2岁)儿童非节段型白癜风受试者中的安全耐受性、疗效和药代动力学特征的多中心、随机、双盲、安慰剂对照II期临床研究申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰恩康(301263.SZ)控股子公司CKBA乳膏申报儿童白癜风临床试验获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2583754815","title":"11月14日泰恩康涨5.06%，鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583754815","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583754815?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:38","pubTimestamp":1763109495,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日泰恩康涨5.06%，收盘报31.36元，换手率3.06%，成交量9.29万手，成交额2.9亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为鹏华基金的鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为9.67亿元，最新净值1.1087，较上一交易日上涨1.72%，近一年上涨40.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400025896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2579945070","title":"泰恩康（301263）股东孙伟文质押300万股，占总股本0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579945070","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579945070?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:41","pubTimestamp":1761907263,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康10月31日公开信息显示，股东孙伟文向华能贵诚信托有限公司合计质押300.0万股，占总股本0.71%。质押详情见下表：截止本公告日，股东郑汉杰已累计质押股份3550.0万股，占其持股总数的40.17%，股东孙伟文已累计质押股份1462.0万股，占其持股总数的22.08%。泰恩康主营业务：代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100040285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2579468139","title":"股市必读：泰恩康三季报 - 第三季度单季净利润同比下降118.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579468139","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579468139?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:34","pubTimestamp":1761770050,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘，泰恩康报收于31.9元，上涨1.4%，换手率1.52%，成交量4.61万手，成交额1.43亿元。来自业绩披露要点：2025年第三季度归母净利润亏损567.96万元，同比下滑118.57%，盈利能力面临压力。股本股东变化股东户数变动近日泰恩康披露，截至2025年9月30日公司股东户数为1.2万户，较6月30日增加1020.0户，增幅为9.32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"gpt_icon":0},{"id":"2579993229","title":"图解泰恩康三季报：第三季度单季净利润同比下降118.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579993229","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579993229?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:48","pubTimestamp":1761677281,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康2025年三季报显示，公司主营收入5.26亿元，同比下降8.13%；归母净利润3140.52万元，同比下降73.0%；扣非净利润3137.89万元，同比下降72.38%；其中2025年第三季度，公司单季度主营收入1.79亿元，同比上升1.02%；单季度归母净利润-567.96万元，同比下降118.57%；单季度扣非净利润-550.17万元，同比下降118.82%；负债率24.84%，投资收益43.45万元，财务费用455.43万元，毛利率55.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"gpt_icon":0},{"id":"2570067200","title":"泰恩康(301263.SZ)：CKBA乳膏玫瑰痤疮适应症开展II/III期无缝适应性临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2570067200","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570067200?lang=zh_cn&edition=full","pubTime":"2025-09-25 17:15","pubTimestamp":1758791702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司控股子公司江苏博创园生物医药科技有限公司(简称“博创园”)收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意CKBA乳膏玫瑰痤疮适应症开展II/III期无缝适应性临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301263","III","BK4134","BK0250"],"gpt_icon":0},{"id":"2568422388","title":"泰恩康(301263.SZ)：甲磺酸沙非胺片药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2568422388","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568422388?lang=zh_cn&edition=full","pubTime":"2025-09-18 16:11","pubTimestamp":1758183095,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)发布公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局(以下简称“国家药监局”)签发的甲磺酸沙非胺片境内生产药品注册上市许可申请《受理通知书》，国家药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的药品注册上市许可申请进行了审查，决定予以受理。甲磺酸沙非胺片是一种选择性抑制B型单胺氧化酶(MAO-B)抑制剂，主要用于治疗成年特发性帕金森氏病(PD)患者，作为稳定剂量的左旋多巴(L dopa)单独或与其他PD治疗联合的附加疗法，用于中晚期波动患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰恩康(301263.SZ)：甲磺酸沙非胺片药品注册上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2566698399","title":"9月9日泰恩康现1笔折价19.61%的大宗交易 合计成交750万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566698399","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566698399?lang=zh_cn&edition=full","pubTime":"2025-09-09 17:06","pubTimestamp":1757408770,"startTime":"0","endTime":"0","summary":"证券之星消息，9月9日泰恩康发生大宗交易，交易数据如下：大宗交易成交价格30元，相对当日收盘价折价19.61%，成交25万股，成交金额750万元，买方营业部为东方证券股份有限公司汕头长平路证券营业部，卖方营业部为东方证券股份有限公司汕头长平路证券营业部。近三个月该股共发生3笔大宗交易，合计成交5475.0手，折价成交3笔。截至2025年9月9日收盘，泰恩康报收于37.32元，下跌0.16%，换手率2.95%，成交量8.95万手，成交额3.38亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090900027304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2564322339","title":"泰恩康(301263.SZ)：地诺孕素片境内生产药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2564322339","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564322339?lang=zh_cn&edition=full","pubTime":"2025-09-04 16:32","pubTimestamp":1756974776,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司安徽泰恩康制药有限公司于近日收到国家药品监督管理局签发的地诺孕素片境内生产药品注册上市许可申请《受理通知书》。地诺孕素作为选择性黄体激素类药物，用于治疗子宫内膜异位症，可缓解疼痛症状、稳定内膜组织，具有耐受性好、不良反应率低的优点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰恩康(301263.SZ)：地诺孕素片境内生产药品注册上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2564842440","title":"股市必读：泰恩康（301263）9月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2564842440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564842440?lang=zh_cn&edition=full","pubTime":"2025-09-02 04:26","pubTimestamp":1756758375,"startTime":"0","endTime":"0","summary":"截至2025年9月1日收盘，泰恩康报收于36.88元，上涨0.44%，换手率2.52%，成交量7.65万手，成交额2.82亿元。交易信息汇总资金流向9月1日主力资金净流入277.58万元；游资资金净流出395.63万元；散户资金净流入118.05万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200004557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2562764367","title":"股市必读：8月27日泰恩康现1笔折价15.27%的大宗交易 合计成交435.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562764367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562764367?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:34","pubTimestamp":1756334082,"startTime":"0","endTime":"0","summary":"截至2025年8月27日收盘，泰恩康报收于34.24元，下跌0.35%，换手率4.12%，成交量12.52万手，成交额4.28亿元。当日关注点来自交易信息汇总：8月27日主力资金净流入2039.46万元，显示主力对泰恩康股票的积极介入。来自交易信息汇总：当日发生1笔折价15.27%的大宗交易，合计成交435.15万元，反映部分股东折价减持或机构间转让。大宗交易8月27日泰恩康现1笔折价15.27%的大宗交易，合计成交435.15万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800007296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0},{"id":"2562751154","title":"股市必读：泰恩康（301263）8月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2562751154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562751154?lang=zh_cn&edition=full","pubTime":"2025-08-27 02:58","pubTimestamp":1756234692,"startTime":"0","endTime":"0","summary":"截至2025年8月26日收盘，泰恩康报收于34.36元，下跌3.07%，换手率1.88%，成交量5.7万手，成交额1.98亿元。董秘最新回复投资者： 您好！请问截至8月20日公司股东户数是多少，谢谢董秘： 尊敬的投资者您好，如您想了解公司的股东人数，请您将持股信息及身份信息发送至公司电子信箱：tekpublic@tnkfun.com，我们在收到您的信息后会及时和您联系。感谢您对泰恩康的关注！当日关注点来自交易信息汇总：8月26日主力资金净流出3595.12万元，显示主力资金明显离场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700003193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2562257759","title":"泰恩康股价下跌3.07% 养老基金二季度新进持仓超1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562257759","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562257759?lang=zh_cn&edition=full","pubTime":"2025-08-27 02:21","pubTimestamp":1756232489,"startTime":"0","endTime":"0","summary":"泰恩康股价报34.36元，较前一交易日下跌1.09元，跌幅3.07%。盘中最高触及35.35元，最低下探至34.35元，成交量为56956手，成交金额达1.98亿元。泰恩康主营业务为医药产品的研发、生产和销售，公司产品涵盖化学药制剂、中成药制剂、原料药等。公司致力于为患者提供高质量的医药产品和服务。公开信息显示，养老基金在二季度新进泰恩康前十大流通股东名单，新增持股市值超过1亿元。数据显示，泰恩康8月26日主力资金净流出3595.12万元，近五日主力资金净流出3694.16万元。风险提示：股市有风险，投资需谨慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/27022152719523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301263","BK0250"],"gpt_icon":0},{"id":"2562262429","title":"股市必读：泰恩康（301263）8月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2562262429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562262429?lang=zh_cn&edition=full","pubTime":"2025-08-25 05:46","pubTimestamp":1756071974,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，泰恩康报收于34.63元，下跌1.03%，换手率1.79%，成交量5.43万手，成交额1.88亿元。董秘最新回复投资者： 董秘您好，请问截止8月10号公司股东数是多少？希望CKBA可以做到白癜风年龄全覆盖。当日关注点交易信息汇总：8月22日，泰恩康主力资金净流出2412.58万元，游资资金净流出413.98万元，而散户资金则净流入2826.56万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500001153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765910686311,"stockEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":-0.1346},{"period":"3month","weight":-0.2685},{"period":"6month","weight":-0.1766},{"period":"1year","weight":0.7363},{"period":"ytd","weight":0.8243}],"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.0133},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.1411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"11961人(较上一季度增加9.32%)","perCapita":"25381股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"42549万元","survey":"　　广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。公司自主研发的“爱廷玖”盐酸达泊西汀片为首个国产PE用药，2020年8月正式投放市场，目前在达泊西汀院外渠道市场稳居头部地位，尤其在线下零售市场形成显著品牌优势。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}